ResearchMoz

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014

Global Markets Direct
Published Date » 2014-02-28
No. Of Pages » 263
 Global Markets Direct’s, ‘Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014’, provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer’s therapeutic pipeline. 
   
 This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic...
Table of Content

Introduction
Global Markets Direct Report Coverage
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview
Therapeutics Development
Pipeline Products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview
Pipeline Products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development
AstraZeneca PLC
Eli Lilly and Company
Viralytics Ltd.
Genentech, Inc.
Bavarian Nordic A/S
Emergent BioSolutions Inc.
Takeda Pharmaceutical Company Limited
Millennium Pharmaceuticals, Inc.
Novartis AG
Astellas Pharma Inc.
GTx, Inc.
Teva Pharmaceutical Industries Limited
Progenics Pharmaceuticals, Inc.
Exelixis, Inc.
Onyx Pharmaceuticals, Inc.
Merck KGaA
Active Biotech AB
Oncolytics Biotech Inc.
Oncothyreon Inc.
Medivation, Inc.
Synta Pharmaceuticals Corp.
Supratek Pharma Inc.
CellCentric Ltd.
CureVac GmbH
GenSpera, Inc.
Bind Therapeutics, Inc.
NewLink Genetics Corporation
Bellicum Pharmaceuticals, Inc.
Bostwick Laboratories, Inc.
ATLAB Pharma SAS
DexTech Medical AB
AbbVie Inc.
Sotio a.s.
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
enzalutamide - Drug Profile
orteronel - Drug Profile
custirsen sodium - Drug Profile
tasquinimod - Drug Profile
enzalutamide - Drug Profile
cabozantinib (s)-malate - Drug Profile
Prostvac - Drug Profile
DCVAC/PCa - Drug Profile
patupilone - Drug Profile
DI-17-E-6 - Drug Profile
olaratumab - Drug Profile
navitoclax - Drug Profile
vandetanib - Drug Profile
PSMA ADC - Drug Profile
GTx-758 - Drug Profile
linsitinib - Drug Profile
olaparib - Drug Profile
panobinostat - Drug Profile
carfilzomib - Drug Profile
ganetespib - Drug Profile
pelareorep - Drug Profile
PX-866 - Drug Profile
CV-9103 - Drug Profile
G-202 - Drug Profile
docetaxel targeted nanoparticles - Drug Profile
buparlisib hydrochloride - Drug Profile
NLG-8189 - Drug Profile
Adenovirus/PSA Vaccine - Drug Profile
TL-118 - Drug Profile
CV-9104 - Drug Profile
Dendritic Cell Vaccine + [docetaxel] - Drug Profile
ATL-101 - Drug Profile
Anti-PSMA Designer T Cells - Drug Profile
CreaVax-PC - Drug Profile
VDC-2008 - Drug Profile
BPX-101 - Drug Profile
CFG-920 - Drug Profile
Osteodex - Drug Profile
CVA-21 - Drug Profile
RG-7450 - Drug Profile
BPX-201 - Drug Profile
ONC-1-13B - Drug Profile
ES-414 - Drug Profile
Deubiquitinase Program - Drug Profile
cabazitaxel nanoformulation - Drug Profile
Compound 54 - Drug Profile
Cannabinoid Receptors Agonists - Drug Profile
ABS-001 - Drug Profile
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Recent Pipeline Updates
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Product Development Milestones
Featured News & Press Releases

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables


Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2014
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Development by Companies, H1 2014 (Contd..1)
Number of Products under Development by Companies, H1 2014 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Development, H1 2014
Products under Development by Companies, H1 2014
Products under Development by Companies, H1 2014 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AstraZeneca PLC, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Eli Lilly and Company, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Viralytics Ltd., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Genentech, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bavarian Nordic A/S, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Emergent BioSolutions Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Novartis AG, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Astellas Pharma Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GTx, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Progenics Pharmaceuticals, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Exelixis, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Merck KGaA, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Active Biotech AB, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncolytics Biotech Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncothyreon Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Medivation, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Supratek Pharma Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CellCentric Ltd., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CureVac GmbH, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GenSpera, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bind Therapeutics, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by NewLink Genetics Corporation, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bostwick Laboratories, Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ATLAB Pharma SAS, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by DexTech Medical AB, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AbbVie Inc., H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Sotio a.s., H1 2014
Assessment by Monotherapy Products, H1 2014
Assessment by Combination Products, H1 2014
Number of Products by Stage and Target, H1 2014
Number of Products by Stage and Mechanism of Action, H1 2014
Number of Products by Stage and Route of Administration, H1 2014
Number of Products by Stage and Molecule Type, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Recent Pipeline Updates, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects, H1 2014
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products, H1 2014

List of Figures


Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2014
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Products, H1 2014
Assessment by Monotherapy Products, H1 2014
Number of Products by Top 10 Target, H1 2014
Number of Products by Stage and Top 10 Target, H1 2014
Number of Products by Top 10 Mechanism of Action, H1 2014
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
Number of Products by Top 10 Route of Administration, H1 2014
Number of Products by Stage and Top 10 Route of Administration, H1 2014
Number of Products by Top 10 Molecule Type, H1 2014
Number of Products by Stage and Top 10 Molecule Type, H1 2014

Upcoming Reports:

Poland: charcoal market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the charcoal market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the charcoal market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main...
Greece: market of printed childrens books
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the printed childrens books market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the printed childrens books market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an...
Data Center UPS Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
The growing trend towards cloud computing, virtualization and the need for easy data availability is fueling the market for data center UPS (Uninterrupted Power Supply). This has increased the number of UPS installations in organizations and has allowed them to use power effectively and efficiently. The use of data centers is growing in organizations for processing & distribution of large data in an uninterrupted manner. UPS provides continuous power supply to these data centers and protects it against power disruptions. With the growing software industry and online...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Cable-free Charging Device Launched by the UPV
Aug 21, 2014  
A wireless energy transfer technology device has been developed by the researchers at the Universitat Politecnica de Valencia (UPV). The striking feature of this device is that one can charge electronic devices like laptops and mobile phones without using cables.  This patented system of the UPV makes use of resonators which have photonic crystals in which one is set on the...
Public Sector Employees Now Less Confident of Their Post-Retirement Security
Aug 21, 2014  
A new analysis reveals that employees in the public sector in the United States are more anxious today about their post-retirement safety than they were just two years ago.   The analysis says that only 18% of all full-time public sector employees that were a part of the survey said that they were ‘very confident’ about their post-retirement income security. This is a 3%...
Novartis to Handover Experimental TB drug to TB Alliance
Aug 21, 2014  
Novartis has signed a deal with the Global TB Alliance to handover its experimental tuberculosis medicine for further development and deployment, for no monitory gains it seems.  The deal is a clear indication how scrutiny over the company’s portfolio has been increased since Joerg Reinhardt took position as company’s new chairman. The new chairman is seen focusing more on...
China Market Loses Pace Again
Aug 21, 2014  
The Chinese manufacturing industry showed a weakening growth in August, which could mean that the world’s second-largest economy may soon have to take precautionary measures. HSBC’s manufacturing index’s preliminary version, which was released on Thursday, showed the Chinese index to decline to 50.3 from its 51.7 in July. The scale is a regular 100-point index, with a...
Does Chewing Gum Lead to Academic Productivity?
Aug 20, 2014  
Could chewing gum actually lead to improved academic productivity? A study conducted recently has found that there may possibly be a link between the two, finally making some headway in a decade-old research. The study called ‘The Effects of Gum Chewing on Math Scores in Adolescents’ was led by Craig Johnston from Baylor College of Medicine in Houston, Texas, and was sponsored by...